Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SM 04755

Drug Profile

SM 04755

Alternative Names: SM-04755

Latest Information Update: 28 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samumed
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis
  • Preclinical Psoriasis; Scleroderma
  • No development reported Tendinitis
  • Discontinued Colorectal cancer; Gastric cancer; Liver cancer; Pancreatic cancer

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for phase-I development in Tendinitis(In volunteers) in USA (Topical)
  • 04 Sep 2018 Samumed terminates a phase I trial in Plaque psoriasis based on various commercial factors in Australia (Topical) (ACTRN12617001178336)
  • 13 Jun 2018 Pharmacodynamics data from a preclinical trial in Tendinitis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top